Document is current
Any future updates will be listed below
-
Authors
Essibayi, Muhammed Amir
Kakadiya, Jay
Salim, Hamza Adel
Chen, Huanwen
Azzam, Ahmed Y.
Dmytriw, Adam A.
Yedavalli, Vivek S
Kassar, Mohammad A.
Colasurdo, Marco
Gandhi, Dheeraj
Khatri, Deepak
Haranhalli, Neil
Altschul, David J.
Lakhani, Dhairya A.
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (U54 GM104942)
- License Information
-
More Information
Article History
Received: 13 February 2026
Revised: 28 April 2026
Accepted: 30 April 2026
First Online: 9 May 2026
Declarations
:
: TriNetX has been granted a waiver from the Institutional Review Board. This is because, as a federated network, any data displayed on the TriNetX Platform (whether in aggregate form or as patient-level data in a generated dataset) contains only de-identified data, adhering to the de-identification standard defined in Section ยงย 164.514(a) of the HIPAA Privacy Rule.
: As the TriNetX lacks patient identifiers, this study was exempt from institutional review board approval.
: As the TriNetX lacks patient identifiers, this study was exempt from informed consent requirements.
: Not applicable.
: Dhairya A Lakhani, MD.
: David Altschul reports securities holdings in Von Vascular, Inc, and compensation from Johnson and Johnson International, Stryker Corporation, Medtronic USA, Inc, and MicroVention, Inc, for consultant services. Vivek Yedavalli is consultant for iSchemaView, RapidAI. Dheeraj Gandhi receives research grants from the Focused Ultrasound Foundation, NIH, University of Maryland Medical Center, and Microvention, and is a consultant for Navigantis. Dhairya Lakhani is consultant for iSchemaView, RapidAI and Scientific advisory board member for Upstream Vision.
